Chronic Hand Eczema (CHE) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Chronic Hand Eczema (CHE) Emerging Therapy and TPP Insights

Thelansis's "Chronic Hand Eczema (CHE) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chronic Hand Eczema (CHE) Overview

Chronic Hand Eczema is a persistent inflammatory skin disorder driven by epidermal barrier dysfunction, immune dysregulation involving Th2 and Th1 pathways, and repeated exposure to irritants or contact allergens. It presents with erythema, vesicles, fissuring, hyperkeratosis, and pruritus predominantly affecting the dorsal hands and fingers, with occupational exposure frequently implicated. Diagnosis is clinical, supported by patch testing to identify contact sensitization; IGA scoring and disease duration reflect severity. Topical corticosteroids and emollients form first-line therapy; alitretinoin is indicated for refractory hyperkeratotic disease, and delgocitinib cream represents a newer topical JAK inhibitor option. Trigger avoidance and barrier protection are essential. Regular severity assessment guides escalation; occupational counseling and psychological support underpin quality-of-life management.

Key Highlights

• In Germany, diagnosed CHE cases are projected to increase from approximately 305,284 in 2025 to 337,306 by 2035.
• CHE remains a chronic inflammatory skin disorder associated with significant quality-of-life impairment and occupational burden.
• Persistent itching, pain, and skin barrier dysfunction continue to drive long-term disease burden.
• Treatment resistance and frequent disease recurrence remain key unmet clinical needs.
• Emerging targeted dermatology therapies are improving management options for moderate-to-severe disease.

Market Overview

• The France CHE market is projected to grow from approximately $155 MN to $420 MN by 2035.
• Market growth is supported by:
• Increasing adoption of advanced topical and systemic therapies
• Growing recognition and diagnosis of chronic disease cases
• Market expansion is driven by prolonged treatment duration and unmet therapeutic need.
• Future growth will depend on innovative targeted immunomodulatory treatments and personalized dermatology approaches.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Incyte Corporation
• LEO Pharma